{"doi":"10.1016/j.xjon.2025.06.005","title":"Surgical management of both stage III and stage IV pulmonary carcinoid tumors confers survival benefit","abstract":"Objective: Pulmonary carcinoid tumors are an uncommon entity, with an incidence of 1.35 cases per 100,000 individuals. Although decisions about surgical resection are commonly made similarly to those for non-small cell lung cancer, data surrounding the optimal treatment and prognostication for patients with advanced disease are limited. Thus, we sought to examine patterns of treatment, risk factors, and outcomes for advanced-stage pulmonary carcinoid tumors. Methods: We retrospectively reviewed healthcare system-wide data from an ongoing, prospectively followed primary lung cancer cohort to identify patients with stage III and IV pulmonary carcinoid tumors from 1997 to 2016, followed through 2023, and analyzed using multivariable Cox modeling and Kaplan-Meier estimates. Results: 010). Conclusions: Advanced-stage pulmonary carcinoid tumors are a rare entity, infrequently described in the literature. Through a large retrospective analysis spanning 26 years, we have identified risk factors associated with mortality for advanced-stage pulmonary carcinoid tumors and demonstrated a potential role for surgical therapy in stage IV disease.","journal":"JTCVS Open","year":2025,"id":568681,"datarank":0.0,"base_score":0.0,"endowment":0.0,"self_citation_contribution":0.0,"citation_network_contribution":0.0,"self_endowment_contribution":0.0,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":0,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":0.9599,"is_data_producer":false,"deposit_databanks":null,"is_oa":true,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":"2025-01-01","fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":1140530,"name":"Pedro Reck dos Santos","orcid":"0000-0002-5497-3188","position":1,"is_corresponding":false},{"id":1250774,"name":"Zhong Gu","orcid":null,"position":2,"is_corresponding":false},{"id":787906,"name":"Matthew Buras","orcid":"0000-0001-6503-0989","position":3,"is_corresponding":false},{"id":1404023,"name":"Juan Farina","orcid":"0000-0002-5824-8485","position":4,"is_corresponding":false},{"id":1120010,"name":"Nathan Y. Yu","orcid":"0000-0003-4059-650X","position":5,"is_corresponding":false},{"id":1250187,"name":"Yanmei Peng","orcid":"0000-0002-7801-8994","position":6,"is_corresponding":false},{"id":429041,"name":"Jason A. Wampfler","orcid":"0009-0007-6918-8135","position":7,"is_corresponding":false},{"id":1473834,"name":"Cecilia Benz","orcid":null,"position":8,"is_corresponding":false},{"id":254872,"name":"Vinicius Ernani","orcid":"0000-0002-1865-5801","position":9,"is_corresponding":false},{"id":531104,"name":"Jonathan D’Cunha","orcid":null,"position":10,"is_corresponding":false},{"id":55500,"name":"Stephen D. Cassivi","orcid":"0000-0001-9600-0897","position":11,"is_corresponding":false},{"id":429043,"name":"Ping Yang","orcid":"0000-0002-8588-847X","position":12,"is_corresponding":false},{"id":1473517,"name":"Jan Jenkins","orcid":"0000-0003-4925-7942","position":0,"is_corresponding":true}],"reference_count":23,"raw_metadata":null,"created_at":"2026-07-19T02:56:55.795846Z","pmid":"40923056","pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}